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Patented Antibody Brings Professor’s Research Closer to Helping 
Diabetics 
 
CEDARVILLE, OHIO – Amid lectures and grading papers, one professor has helped engineer and test an 
antibody that has potential to treat the results of a multitude of vascular conditions, including pain in walking 
and limb necrosis associated with late-stage diabetes.   
  
Dr. Rocco Rotello, associate professor of pharmaceutical sciences at Cedarville University, has secured a 
patent for his seven-year antibody research and is steadily approaching a treatment for a multitude of vascular 
conditions. 
  
The object of Rotello’s patented research is an engineered antibody. Antibodies are proteins that act as keys 
that fit biological locks on certain cells to initiate a process within the cell. Rotello’s antibody is designed for 
compatibility with endothelial cells. 
  
Endothelial cells form the interior walls of blood vessels (arteries, veins and capillaries), the passageways for 
blood to and from the heart. When endothelial cells are healthy, they ensure blood flows correctly by keeping 
the vessel walls strong and stable. If the cells are unhealthy, the vessel walls may leak, which can lead to a 
host of issues, including irregular blood pressure, clotting and edema.   
  
Rotello’s patented antibody flips the switch that sends endothelial cells into survival mode, which strengthens 
the walls of blood vessels. As a result, the antibody, which is injected into a subject, has the potential to treat 
numerous vascular conditions. 
  
While various treatments currently exist for improving blood flow in the heart, such as stents, Rotello’s antibody 
will be the first of its kind to promote blood flow to the limbs, hands and feet. The goal is to alleviate debilitating 
pain, limb death and amputation that would otherwise occur.   
  
Rotello expects that human drug trials will begin in late 2019 and a final treatment may be widely available by 
2023. 
  
Located in southwest Ohio, Cedarville University is an accredited, Christ-centered, Baptist institution with an 
enrollment of 3,963 undergraduate, graduate, and online students in more than 150 areas of study. Founded in 
1887, Cedarville is recognized nationally for its authentic Christian community, rigorous academic programs, 
strong graduation and retention rates, accredited professional and health science offerings, and leading student 
satisfaction ratings. For more information about the University, visit www.cedarville.edu. 
 
